HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

The efficacy of Nervo-Vit in premenopausal patients: its effect on social activity, anxiety, and quality of life

DOI: https://doi.org/10.29296/25877305-2022-05-05
Issue: 
5
Year: 
2022

M. Khabibulina, Candidate of Medical Sciences; M. Shamilov
Ural State Medical University, Yekaterinburg

The natural sedative drug Nervo-Vit was studied for its effect on quality of life (QoL), anxiety, and social activity in 58 premenopausal patients with hypoestrogenemia. The health, activity, mood questionnaire and Short form 36 (SF-36) Health Quality Survey questionnaire were used. The Hospital Anxiety and Depression Scale (HADS) was employed to assess psychological characteristics. The stressful impact of estrogen deficiency on the social aspects of life in the examinees was measured by visual and spatial subscales (D.V. Sheehan). Therapy with Nervo-Vit has been established to have a positive impact on the psychological state, social aspects, and QoL of premenopausal women with estrogen deficiency.

Keywords: 
therapy
quality of life
anxiety
social functioning
premenopause
hypoestrogenemia
Nervo-Vit



References: 
  1. Chazova I.E., Smetnik V.P., Balan V.E. Vedenie zhenshchin s serdechno-sosudistym riskom v peri- i postmenopauze:konsensus rossiiskikh kardiologov i ginekologov. Consilium medicum. 2008; 10 (6): 5–18 (in Russ.).
  2. Skornyakova M.N., Syrochkina M.A. Gipomenstrual’nyi sindrom. Rukovodstvo dlya vrachei. Ekaterinburg, 2008; 236 s. (in Russ.).
  3. Smetnik V.P., Il’ina L.M. Korrektsiya klimaktericheskogo sindroma (individualizatsiya terapii). V kn. «Meditsina klimakteriya». Litera, 2006; s. 217–74 (in Russ.).
  4. Khabibulina M.M. Kardiovaskulyarnyi risk pri estrogenodefitsite v doklimaktericheskikh periodakh.Yekaterinburg, 2014 (in Russ.).
  5. Blumel J.E., Castello C. et al. Quality of life after the menopause – a population study. Maturitas. 2009; 34 (1): 17–23. DOI: 10.1016/s0378-5122(99)00081-x
  6. Khabibulina M.M. Effect of hypoestrogenemia on quality of life of premenopausal women with arterial hypertension. Kardiologiya. 2013; 53 (11): 45–8 (in Russ.).
  7. Khabibulina M.M., Dmitriev A.N., Fedorova N.N. Kachestvo zhizni molodykh zhenshchin s arterial’noi gipertenziei s gipoestrogenemiei s «metabolicheski zdorovym» vistseral’nym ozhireniem. Evraziiskii Soyuz Uchenykh. 2017; 1 (34): 25–9 (in Russ.).
  8. Khabibulina M., Shamilov M. Quality of life in young women with hypertension and an altered hormonal background. Vrach. 2021; 32 (1): 46–9 (in Russ.). DOI: 10.29296/25877305-2021-01-09
  9. Stein K.D., Jacobsen P.B. Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. J Pain Symptom. 2009; 19: 436–45.
  10. Khabibulina M., Shamilov M. The effect of glycine and lisinopril on quality of life in women with hypertension and estrogen deficiency Vrach. 2021; 32 (4): 38–42 (in Russ.). DOI: 10.29296/25877305-2021-04-06
  11. Gavrilova N.P., Seliverstov P.V., Ayrapetyan M.S. et al. Ursodeoxycholic acid in combination with menopausal hormone therapy corrects metabolic abnormalities in postmenopausal women with non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2019; 168 (8): 77–81 (in Russ.). DOI: 10.31146/1682-8658-ecg-168-8-77-81
  12. Khabibulina M.M., Smolentseva A.A. Terapiya trevozhnykh rasstroistv u zhenshchin s arterial’noi gipertenziei v period premenopauzy na ambulatornom etape. V sb.: V s»ezd kardiologov Ural’skogo federal’nogo okruga. Mat-ly s»ezda. 2011; s. 282–4 (in Russ.).
  13. Menopauzal’naya gormonal’naya terapiya i sokhranenie zdorov’ya zhenshchin zrelogo vozrasta: Klinicheskie rekomendatsii (protokol lecheniya). M.: FGBU NTsGAiP, 2015 (in Russ).
  14. Pines A., Sturdee D.W., Birkhauser M.H. IMS Updated Recommendations on postmenopausal hormone therapy. Climacteric. 2007; 10 (3): 195–6. DOI: 10.1080/13697130701361657
  15. Khabibulina M.M., Dmitriev A.N. Sposob optimizatsii lecheniya zhenshchin kardiotropnoi terapiei i zamestitel’noi gormonal’noi terapiei pri estrogenodefitsite s arterial’noi gipertenziei v pozdnem reproduktivnom periode. Patent na izobretenie RU 2648470 C2, 26.03.2018 Zayavka №2016107890 ot 03.03.2016 (in Russ.).
  16. Khabibulina M. Therapy in women with hypertension and estrogen deficiency in the late fertile period. Vrach. 2016; 4: 45–9 (in Russ.).
  17. Doskin V.A., Lavrent’eva N.A., Miroshnikov M.P. Test differentsial’noi samootsenki funktsional’nogo sostoyaniya. Voprosy psikhologii. 1999; 6: 48–54 (in Russ.).
  18. Novik A.A., Ionova T.I. Rukovodstvo po issledovaniyu kachestva zhizni v meditsine. SPb: Izdatel’skii dom «Neva», M.: «OLMA-PRESS Zvezdnyi mir», 2002; 320 s. (in Russ.).
  19. Ware J.E. Measuring patients’ views: the optimum outcome measure. SF 36: a valid, reliable assessment of health from the patient’s point of view. BMJ. 1993; 306 (6890): 1429–30. DOI: 10.1136/bmj.306.6890.1429
  20. Ware J.E., Gandek B. Overview of the SF-36 Health Surveg and the International anality of Life Assessment (JQOLA). Projekt J Clin Epidemiol. 1998; 51 (11): 903–12. DOI: 10.1016/s0895-4356(98)00081-x
  21. The WHOQOL Group. What Quality of Life? The WHOQOL Group. World Health Forum. 1996; 17 (4): 354–6.
  22. Zigmond A.S., Snaith R.P. Тhe hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67: 361. DOI: 10.1111/j.1600-0447.1983.tb09716.x
  23. Sheehan D.V., Harnett-Sheehan K., Raj B.A. The measurement of disability. Int Clin Psychopharmacol. 1996; 11 (3, Suppl.): 89–95. DOI: 10.1097/00004850-199606003-00015